| Document |
Document Title |
|
WO/2023/107825A1 |
Provided herein, among other things, is a cytotoxic immune cell (e.g., a cytotoxic T cell) that expresses an engineered immune receptor (such as a CAR or TCR) whose cytotoxicity within the tumor microenvironment is enhanced by a pro-infl...
|
|
WO/2023/104168A1 |
Disclosed are a chimeric antigen receptor and a chimeric antigen receptor T cell targeting both GPC3 and CD276, a preparation method therefor and use thereof. Experiments show that a chimeric antigen receptor T cell targeting both GPC3 a...
|
|
WO/2023/102862A1 |
The present invention relates to the field of immobilized proteins, in particular to a method for preparing a polyhedra for wrapping foreign proteins. A bombyx mori cytoplasmic polyhedrin, and a fusion foreign protein having a bombyx mor...
|
|
WO/2023/106279A1 |
Provided is a method for producing a target protein using a plant as an expression host. A target protein is produced by expressing the target protein using a plant modified to express ERp27 and/or TMX1 as an expression host.
|
|
WO/2023/104822A1 |
The present invention relates to chimeric polypeptides comprising adiponectin, nucleic acids encoding said chimeric polypeptides, and extracellular vesicles comprising said chimeric polypeptides. It further relates to the use of said ext...
|
|
WO/2023/103005A1 |
Provided are a method for enriching an antibody by using an affinity chromatography medium and the use thereof. The method comprises: (1) cross-linking an antigen and GST by mean of glutaraldehyde to form an antigen-GST complex; (2) conn...
|
|
WO/2023/104171A1 |
Disclosed are a chimeric antigen receptor T cell secreting bispecific antibodies, a preparation method therefor and use thereof. Experiments show that a chimeric antigen receptor T cell targeting GPC3 and secreting bispecific antibodies ...
|
|
WO/2023/104134A1 |
Provided are antibody-cytokine fusion proteins comprising an anti-PD-L1 antibody and an Interleukin 21, and methods for preparing the same, as well as applications of the fusion proteins for therapeutic purpose.
|
|
WO/2023/101007A1 |
The present invention provides: a vector that expresses a fusion protein containing a secretion signal, an antigen-protein fragment, and a trimer forming domain; and usages thereof. Said vector has an excellent ability to secrete and rel...
|
|
WO/2023/102221A1 |
Provided herein are engineered Cas13 proteins with enhanced collateral activity. The engineered proteins comprise RNA binding domains (RBDs) fusions within an active site- proximal loop within a higher eukaryotes and prokaryotes nucleoti...
|
|
WO/2023/097407A1 |
The present disclosure relates to amatoxin analogs comprising one or more modifications of eastern ring residues, constructs comprising such amatoxin analogs coupled to a linker and conjugates comprising such amatoxin analogs or compound...
|
|
WO/2023/100829A1 |
The present invention provides a novel MuSK antibody. The present invention provides a molecule which binds to a target antigen, and is characterized by comprising a region that binds to the target antigen, a first peptide that recogni...
|
|
WO/2023/288007A9 |
The present disclosure generally relates to, inter alia, natural killer (NK) cells including memory-like and cytokine-induced memory like (CIML) NK cells, methods of making and using them e.g. in the treatment of cancer, increasing anti-...
|
|
WO/2023/102541A1 |
Disclosed herein is an engineered eukaryotic cell which expresses a heterologous G protein coupled receptor (GPCR), wherein native Ste2 and/or Ste3 have been replaced with a heterologous GPCR; and further wherein native G alpha protein (...
|
|
WO/2023/093888A1 |
Provided are preparation and a use of immune cells of a chimeric antigen receptor (CAR) constructed on the basis of EFNA1. Specifically, provided is a CAR modified on the basis of EFNA1, the CAR comprises an extracellular binding domain,...
|
|
WO/2023/095913A1 |
The present invention provides a technology for improving agonist activity of a human TNFR2 agonist, and a technology for selectively increasing effector Treg. This polypeptide contains a human TNFR2 agonist domain and an oligomerization...
|
|
WO/2023/093020A1 |
Provided are an Fc fragment mutant, a fusion protein, a nucleic acid molecule, an expression vector, a recombinant cell, a pharmaceutical composition and use thereof, and a method for preventing and/or treating a disease associated with ...
|
|
WO/2023/093831A1 |
The present invention relates to a bifunctional fusion protein, which includes a first binding domain that specifically binds to CLDN18.2, and a second binding domain that specifically binds to a CD47 protein, wherein the second binding ...
|
|
WO/2023/093811A1 |
The present invention relates to a molecular switch regulation type chimeric antigen receptor polypeptide, containing a humanized anti-P329G mutant scFv sequence, a hinge region/spacer region, a transmembrane region, a costimulatory sign...
|
|
WO/2023/092324A1 |
The present invention relates to a ligand binding molecule capable of binding one or more growth factors comprising VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, PDGF-AA, PDGF-AB, PDGF-BB, and PDGF-CC, a glycosylation modified molecule thereof, ...
|
|
WO/2023/092452A1 |
The present invention provides a T cell receptor (TCR) for specifically identifying an EBV LMP2 antigen, a conjugate and a fusion protein comprising the TCR, an immune cell expressing the TCR, a T cell drug containing the TCR, and the us...
|
|
WO/2023/093303A1 |
Disclosed in the present invention are a P53-targeted polypeptide and a use thereof in preparation of a drug for treating cancer. The polypeptide specifically binds to a P53 mutant, and the polypeptide is selected from any one or more of...
|
|
WO/2023/087255A1 |
Provided in the present invention are a bispecific antibody and the use thereof. The bispecific antibody contains an antigen-binding domain specifically binding to EpCAM and an antigen-binding domain specifically binding to CD3.
|
|
WO/2023/087823A1 |
Provided are a mitochondrial positioning polypeptide, a positioning system, and a use thereof. The mitochondrial positioning polypeptide is selected from: (a) a polypeptide composed of any of the amino acid sequences shown in SEQ ID NO. ...
|
|
WO/2023/091875A1 |
A bi-functional fusion protein that inhibits a complement signaling pathway is provided, the bi-functional fusion protein comprises a complement C4b binding motif, a complement C3b binding motif, and an Fc region. A method of treating or...
|
|
WO/2023/087090A1 |
The invention relates to recombinant proteins useful in the treatment of diseases or disorders associated with MBL-2 deficiency. The invention also relates to nucleic acids encoding such recombinant proteins, expression vector comprising...
|
|
WO/2023/088429A1 |
Provided are a SIRPα variant and a fusion protein thereof, capable of specifically blocking interaction between CD47 protein and SIRPα, not causing coagulation reaction, and capable of inhibiting growth and/or proliferation of tumors o...
|
|
WO/2023/089500A1 |
Provided are variant B-cell maturation antigen (BCMA) cysteine-rich domain (CRD) molecules capable of binding to ligands B-cell Activating Factor of the TNF family (BAFF) and A Proliferation Inducing Ligand (APRIL) with higher affinity c...
|
|
WO/2023/088359A1 |
Provided in the present invention is a BCMA-targeting chimeric antigen receptor, comprising an extracellular antigen recognition domain, a hinge region, a transmembrane region and an intracellular domain. The extracellular antigen recogn...
|
|
WO/2023/090409A1 |
In one embodiment, the present invention pertains to a peptide having affinity for the human transferrin receptor, and to applications of the same, wherein in order to pass through the blood-brain barrier, the peptide can be used by bind...
|
|
WO/2023/092094A2 |
The present disclosure relates to chimeric small molecules, which find utility as modifiers of target substrates according to the formula A-L1-E-B or A-L1-E-L2-B, wherein A is a kinase binding moiety; B is a target binding moiety; L1 and...
|
|
WO/2023/088351A1 |
Provided is the use of a nerve growth factor in the preparation of a drug for treating or improving diseases of the reproductive system.
|
|
WO/2023/085418A1 |
The present invention addresses the problem of providing a fusion protein that is intended to be used in the treatment of a viral disease and is formed from a virus-inhibiting molecule and a streptavidin variant. According to the present...
|
|
WO/2023/083327A1 |
The present invention provides an anti-CLDN18.2 monoclonal antibody and a preparation thereof. Specifically, the present invention provides a novel anti-CLDN18.2 humanized antibody. The antibody of the present invention may highly-specif...
|
|
WO/2023/086796A2 |
Provided are methods for treating cancer by converting tumor-resident macrophages into a hybrid M1/M2 macrophage phenotype; this phenotype has attributes that are advantageous for cancer therapy. Hybrid markers include (lower than M2, hi...
|
|
WO/2023/086929A1 |
The present disclosure relates, in part, to compositions and methods, including chimeric proteins, that find use in the treatment of disease, such as immunotherapies for cancer.
|
|
WO/2023/086900A1 |
The present disclosure provides compositions and methods comprising chimeric antigen receptors (CARs) specific for amyloid beta (Αβ) and/or Tau. In certain embodiments, the CARs do not comprise an intracellular domain. Methods of treat...
|
|
WO/2023/083243A1 |
The present invention relates to the technical field of fusion proteins, and relates in particular to an anti-IL-17/VEGF bifunctional fusion protein and a use thereof. The anti-IL-17/VEGF bifunctional fusion protein comprises an anti-IL-...
|
|
WO/2023/082022A1 |
There is described herein polyvalent HCV vaccines, preferably comprising SEQ ID Nos. 1-5. There is also described herein methods of designing polyvalent vaccines.
|
|
WO/2023/081959A1 |
An immunotherapeutic protein and methods of use and production thereof are disclosed, wherein the immunotherapeutic protein comprises one or more immunoglobulin heavy chain polypeptide comprising an Fc region component comprising at leas...
|
|
WO/2023/083379A1 |
The present invention relates to a fusion protein construct taking interleukin 15 as an active ingredient and the use thereof. Specifically, the fusion protein construct comprises: (1) a first structural unit: an α subunit sushi domain ...
|
|
WO/2023/083250A1 |
Provided herein are genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD2, and methods of use thereof.
|
|
WO/2023/086896A1 |
Disclosed is a method of treating a subject having a malignant glioma comprising: administering by convection-enhanced delivery (CED) for a period of up to 96 hours a therapeutically effective amount of a mutagenized IL13 linked to a cyt...
|
|
WO/2023/078438A1 |
A mycobacterium tuberculosis (MTB) fusion protein, a preparation method therefor and a use thereof. The MTB fusion protein is composed of two proteins, EAST6 and CFP10, has six connection structures, namely EEC, ECE, CEE, ECC, CEC and CC...
|
|
WO/2023/078245A1 |
Provided are an IL-10 monomer fusion protein and a use thereof, which relate to the field of biomedicine. The fusion protein comprises an antibody and an IL-10 monomer. The fusion protein of the present invention has a relatively strong ...
|
|
WO/2023/077943A1 |
Provided are a bispecific chimeric antigen receptor targeting an HIV-1 envelope protein. The chimeric antigen receptor comprises: (1) a recognition unit targeting an HIV-1gp120 protein co-receptor binding site; (2) a recognition unit tar...
|
|
WO/2023/077206A1 |
This invention consists of genetically modified epitopes and multiepitope proteins composed of these genetically modified epitopes to avoid the formation of neoepitopes. The multiAAA protein is composed of genetically modified epitopes b...
|
|
WO/2023/077210A1 |
Generally, the present disclosure provides novel bacterial translocation domains for use in cellular delivery. An example is the translocation domain from the Austwickia chelonae protein of SEQ ID NO:2, the translocation domain having th...
|
|
WO/2023/077924A1 |
An anti-tumor fusion protein, wherein the fusion protein can inhibit the growth of MUC1-positive tumor cells, and can inhibit the growth of pancreatic cancer tumor cells. The fusion protein has broad application prospects for the prevent...
|
|
WO/2023/081754A1 |
Disclosed are cluster CAR and therapeutic payload nucleic acids, immune cells containing them, and uses thereof for controllable adoptive cell therapy and killing CAR T-cell resistant tumor cells.
|
